Gilead Sciences: Why I'm Tempted To Sell Ahead Of Q1 Earnings - But Won't [Seeking Alpha]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Seeking Alpha
Despite a recent $11bn M&A spree targeting oncology and immunology, GILD faces skepticism due to a poor track record and lack of near-term revenue from new acquisitions. I expect Q1 earnings to be somewhat underwhelming, with sluggish growth and minor IPR&D charges, but GILD trades at a below-average forward P/E of ~16x versus peers. I continue to hold GILD for its robust HIV franchise and 2% dividend yield while awaiting evidence that management can successfully execute on oncology ambitions. Haggerston BioHealth members get exclusive access to our real-world portfolio. See all our investments here » Michael Vi/iStock Editorial via Getty Images Investment Overview - Background To Q1 Earnings & M&A Spree Gilead Sciences, Inc. ( GILD ), the Foster City, California-based Pharma giant, is set to announce its Q1 earnings on 23rd April - this Thursday. Analysts' consensus revenue More on my IG service If you are interested in keeping up to date with stocks making moves wit
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Arcus halts Gilead-partnered late-stage trial for lung cancer drug [Seeking Alpha]Seeking Alpha
- Citi Raises Gilead (GILD) Price Target Ahead of Q1 Biopharma Preview [Yahoo! Finance]Yahoo! Finance
- Jim Cramer on Gilead Sciences: “I'd Hold On to It” [Yahoo! Finance]Yahoo! Finance
- Gilead Sciences (GILD) had its price target raised by The Goldman Sachs Group, Inc. from $125.00 to $130.00. They now have a "neutral" rating on the stock.MarketBeat
- Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender OfferBusiness Wire
GILD
Earnings
- 2/10/26 - Beat
GILD
Sec Filings
- 4/16/26 - Form 4
- 4/16/26 - Form 4
- 4/15/26 - Form 144
- GILD's page on the SEC website